A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

Exclusion Criteria

• •History of/currently active clinically relevant, ocular inflammation or infection
• •Glaucoma or other significant optic neuropathy
• •Diabetic macular edema or diabetic retinopathy
• •Clinically significant cystoid macular edema
• •Spherical equivalent refractive error of greater than 8.00 diopters myopia
• •Ocular surgery ≤3 months before Screening
• •Monocular vision (ie, no light perception in the fellow eye)
• •Presence of clinically significant anti-OpCT-001 Human Leukocyte Antigen (HLA) antibodies at Screening
• •Currently active malignancy, or history of malignancy within 5 years before OpCT-001 administration. Exception: Basal cell carcinoma that has been definitively treated.
• •Any current and active infection (bacterial/viral/fungal) that could put the participant at risk from immunosuppression
• •History of any cell therapy, gene therapy, or retinal implant at any time
• •Previously received a bone marrow or solid organ transplant